SteelPeak Wealth LLC Acquires New Stake in Illumina, Inc. $ILMN

SteelPeak Wealth LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, Holdings Channel reports. The firm acquired 1,952 shares of the life sciences company’s stock, valued at approximately $534,000.

A number of other institutional investors also recently made changes to their positions in ILMN. Baker Tilly Wealth Management LLC boosted its stake in shares of Illumina by 3.3% during the 3rd quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock valued at $355,000 after buying an additional 42 shares during the last quarter. Elevation Wealth Partners LLC grew its position in shares of Illumina by 19.7% during the third quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company’s stock worth $80,000 after buying an additional 48 shares in the last quarter. IFP Advisors Inc grew its position in shares of Illumina by 2.9% during the third quarter. IFP Advisors Inc now owns 1,986 shares of the life sciences company’s stock worth $544,000 after buying an additional 56 shares in the last quarter. Valeo Financial Advisors LLC increased its stake in shares of Illumina by 1.5% in the third quarter. Valeo Financial Advisors LLC now owns 4,031 shares of the life sciences company’s stock worth $1,103,000 after buying an additional 61 shares during the last quarter. Finally, Robertson Stephens Wealth Management LLC increased its stake in shares of Illumina by 0.9% in the third quarter. Robertson Stephens Wealth Management LLC now owns 6,748 shares of the life sciences company’s stock worth $1,847,000 after buying an additional 63 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Trading Up 0.0%

NASDAQ:ILMN opened at $262.66 on Tuesday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The business’s 50 day moving average is $235.94 and its two-hundred day moving average is $187.45. Illumina, Inc. has a 52 week low of $94.00 and a 52 week high of $309.35. The company has a market cap of $39.66 billion, a PE ratio of 50.98, a P/E/G ratio of 3.72 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the firm earned $1.19 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Insider Transactions at Illumina

In related news, Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the transaction, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 2,061,850 shares of company stock worth $436,479,102 in the last quarter. Company insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ILMN shares. Stifel Nicolaus upped their price target on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a report on Friday, July 31st. Guggenheim raised their price objective on shares of Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Citigroup raised their price objective on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a report on Monday, August 3rd. Barclays boosted their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a research report on Wednesday, October 7th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Illumina in a research note on Monday, August 31st. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $231.88.

Illumina Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.